An unusual transmission event of Neisseria meningitidis serogroup W135 type 2a in a healthcare setting, England, 2012

Eurosurveillance

Volumn 17, Issue 44, 2012, Pages

  Puleston, R ^a   Beck, C ^a   Tahir, M ^a   Bardhan, M ^a   Charlemagne, P ^a   Alves, C ^a   Ladhani, S ^a   Watson, C ^a   Ramsay, M ^a   Kaczmarksi, E ^a   Borrow, R ^a   Gray, S ^a   Hadlington, D ^b   Weinbren, M ^c   Bhattacharjee, D ^c   Inglis, N ^d  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b West Midlands Ambulance Service NHS Foundation Trust   (United Kingdom)

^c UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^d University Hospitals Coventry and Warwickshire NHS Trust ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIAL TRANSMISSION; CHEMOPROPHYLAXIS; EPIDEMIC; FATALITY; HEALTH CARE; HUMAN; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS W135 TYPE 2A; PNEUMONIA; PURPURA; SEPTICEMIA; UNITED KINGDOM;

EID: 84877745673     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Meningococcal meningitis and septicaemia notifiable. In: Salisbury D, Ramsay M, Noakes K, editors. Immunisation against infectious disease. The Green Book. London: Department of Health; 2007. p. 235-55.
2. Ladhani SN, Flood JS, Ramsay ME, Campbell H, Gray SJ, Kaczmarski EB, et al. Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccines. Vaccine. 2012;30(24):3710-6.
3. Meningococcal Disease. In: Atkinson W, Wolfe C, Hamborsky J, editors. Epidemiology and Prevention of Vaccine-Preventable Diseases The Pink Book. 12th ed. Washington D.C.: Centers for Disease Control and Prevention, The Public Health Foundation; 2012. p. 203.
4. Caugant DA, Maiden MCJ. Meningococcal carriage and diseasepopulation biology and evolution. Vaccine. 2009;27 Suppl 2:B64-70.
5. Health Protection Agency (HPA) Meningococcus and Haemophilus Forum. Guidance for public health management of meningococcal disease in the UK. London: HPA; 2012. Available from: http://www.hpa.org.uk/webc/HPAwebFile/ HPAweb_C/1194947389261
6. Mohr O, Askar M, Schink S, Eckmanns T, Krause G, Poggensee G. Evidence for airborne infectious disease transmission in public ground transport-a literature review. Eurosurveillance. 2012;17(35):pii=20255. Available from: http://www. eurosurveillance.org/ViewArticle.aspx?ArticleId=20255
7. Hershey JH, Hitchcock W. Epidemiology and meningococcal serogroup distribution in the United States. Clinical Pediatrics (Phila). 2010;49(6):519-24.
8. Ladhani SN, Lucidarme J, Newbold LS, Gray SJ, Carr AD, Findlow J, et al. Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009. Emerg Infect Dis. 2012;18(1):63-70.
9. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180(6):1894-901.
10. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;50 Suppl 2:S37-44.
11. Trotter CL, Fox AJ, Ramsay ME, Sadler F, Gray SJ, Mallard R, et al. Fatal outcome from meningococcal disease-an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin. J Med Microbiol. 2002;51(10):855-60.
12. Buckee CO, Jolley KA, Recker M, Penman B, Kriz P, Gupta S, et al. Role of selection in the emergence of lineages and the evolution of virulence in Neisseria meningitidis. Proc Natl Acad Sci U.S.A. 2008;105(39):15082-7.
13. Ibarz-Pavón AB, Maclennan J, Andrews NJ, Gray SJ, Urwin R, Clarke SC, et al. Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J Infect Dis. 2011;204(7):1046-53.
14. Maiden MCJ, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359(9320):1829-31.
15. Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis. 2003;36(6):679-83.
16. Baron EJ, Miller JM. Bacterial and fungal infections among diagnostic laboratory workers: evaluating the risks. Diagn Microbiol Infect Dis. 2008;60(3):241-6.
17. Centers for Disease Control and Prevention (CDC). Occupational Transmission of Neisseria meningitidis-California, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(45):1480-3.
18. Sejvar JJ, Johnson D, Popovic T, Miller JM, Downes F, Somsel P, et al. Assessing the risk of laboratory-acquired meningococcal disease. J Clin Microbiol. 2005;43(9):4811-4.
19. Wilder-Smith A, Chow A, Goh KT. Emergence and disappearance of W135 meningococcal disease. Epidemiol Infect. 2010;138(7):976-8.